EP-1143 Intensity-Modulated Radiation Therapy (IMRT) in nasopharynx tumors: long term results  by Picardi, V. et al.
3rd ESTRO Forum 2015                                                                                                                                         S621 
 
was found in 21 patients (67.8%) and stable disease (SD) was 
observed in 10 cases (32.2%). SD after chemotherapy was 
reported more often in patients qualified to high expression 
of βT-II, whereas PR in the group of low protein expression 
(p=0.004). The increase in Histoscore (HS) parameter 
obtained from the computer image analysis was correlated 
with the observed lower regression of the tumor (r=–0.43, 
p=0.017). In patients with SD effect observed after induction 
chemotherapy the mean value of HS was 109.5 whereas in 
the PR group the mean value of HS was 28.34. No correlation 
between the response to radiotherapy and βT-II expression 
was found (p=0.92). The difference in 1-year OS and PFS was 
not shown for the patients from neither the high or low βT-II 
expression (OS 75% vs 63%; p=0.69, PFS 63% vs 58%; p=0.69). 
Conclusions: The βT-II protein expression level in tumor 
tissue is a predictive factor for clinical response to taxane-
based neoadjuvant chemotherapy in LASHNC. In the case of 
high βT-II expression the most probable effect of 
chemotherapy is tumor stabilization. Low βT-II expression 
level may be a parameter used to select the patients with 
prognozed good response to TPF chemotherapy. In these 
patients realization of radiotherapy may be easier without 
the risk of delayed definitive treatment.  
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Purpose/Objective: To investigate effects of the epidermal 
growth factor receptor (EGFR) polymorphisms on survival for 
advanced oral cancer patients. 
Materials and Methods: A total of 156 patients with 
advanced oral cancer were treated with a uniform induction 
chemotherapy (Methotrexate 30 mg/m2 D1, Epirubicin 30 
mg/m2 D1, alternating with Mitomycin-C 4 mg/m2 D8, 
Oncovin 1 mg/m2 D8, Cisplatin 25 mg/m2 D8, Leucovorin 120 
mg/m2 D8, 5-fluorouracil 1000 mg/m2 D8, and Bleomycin 10 
mg/m2 D8) for 8-12 weeks followed by local treatment 
(surgery/radiotherapy). Most patients (97.5%) belonged to 
stage IV and 70% presented with unresectable tumor. DNA 
extracted from peripheral blood cells of each patient were 
used for genotyping. Four EGFR polymorphisms, codon 497 
(R497K), CA simple sequence repeat 1 (CA-SSR1) in intron 
one, and two single nucleotide polymorphisms in the 
promoter region (-216 G to T and -191 C to A) were 
examined. Overall survival (OS) and locoregional failure-free 
survival (LRFFS) according to EGFR polymorphisms were 
analyzed. 
Results: The frequencies of the R/R, R/K, and K/K genotypes 
for R497K polymorphism were 26.3%, 48.7%, and 25.0%, 
respectively. The G/G, G/T, and T/T genotypes distribution 
for the -216 G to T polymorphism showed 91.0%, 7.7%, and 
1.3%, respectively. Most patients (86.5%) belong to a longer 
CA repeats (>35 repeat) genotype. For the -191 C to A 
polymorphism, 100% patients were C/C type. Patients with 
heterozygosity of EGFR codon 497 (Arg/Lys) showed better 
survivals (5-year OS=34.9% vs. 23.1%, P=0.1545; 5-year 
LRFFS=46.2% vs. 24.9%, P=0.0663) than those of homozygosity 
(Arg/Arg or Lys/Lys). Better survivals were observed in 
patients with variant SNP -216 G/G genotype than those of -
216 G/T or T/T genotypes (5-year OS=29.4% vs. 11.0%, 
P=0.0661; 5-year LRFFS=36.9% vs. 11.2%, P=0.0179). 
Combined both R497K and -216 G to T polymorphisms have 
more significant effects on OS (P=0.014) and LRFFS (P=0.010). 
The lengths of CA-SSR1 repeats did not affect survival. 
Conclusions: Combination of the R497K and -216 G to T 
polymorphisms of the EGFR is a significant prognostic factor 
in predicting survival for patient with advanced oral cancer. 
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Purpose/Objective: The aim of the study was to report the 
long-term clinical outcomes of nasopharynx cancer patients 
treated with cisplatin based concurrent chemoradiation 
(RCT). 
Materials and Methods: Patients with nasopharynx tumor 
(UICC Stage II-IV) treated with definitive RCT or neoadjuvant 
chemotherapy (NACT: Cisplatin + 5-Fluorouracil (CF) or 
Docetaxel + Cisplatin + 5-Fluorouracil (DCF)) followed by RCT 
from January 2006 to January 2014 were included in the 
analysis. According to a dose-escalation protocol, a total of 
67.5-70.5 Gy in 30 fractions were delivered to primary tumor 
and involved nodes, 60 Gy in 30 fractions to high-risk nodal 
areas, and 55.5 Gy in 30 fractions to low-risk nodal areas. 
Simultaneous integrated boost IMRT/VMAT technique was 
used. Local control and overall survival were estimated by 
the Kaplan-Meier method. 
Results: 26 patients (M/F: 19/7; median age: 55 years; 
range: 30-79 years; UICC stage: II (3 patients), III (8 patients) 
and IV (15 patients)) were treated and analyzed. 3 cycles of 
NACT (CF or DCF) was administered in 21 patients (81%). 15 
patients were treated with IMRT/SIB and 11 with VMAT/SIB. 
Grade 3 or 4 acute toxicities (RTOG score) were: oral 
mucositis (8 patients: 31%); dysphagia (1 patient: 4%); 
dysphonia (2 patients: 8%); hematological suppression (6 
patients: 23%). No Grade 3 or 4 late toxicity (RTOG EORTC 
score) was recorded. The 2- and 5-year local control were 
84% and 60% and 2- and 5-year overall survival were 75% and 
44%, respectively. 
Conclusions: In our experience, a moderately accelerated 
concurrent RCT, even after induction chemotherapy, is 
feasible and well tolerated. Taking into account the 
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preponderance of locally advanced tumors, local control and 
overall survival are encouraging. 
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Purpose/Objective: To asses the clinical utility of 18F-FDG 
PET-CT in patients with advanced head and neck squamous 
cell carcinoma (HNSCC), considering the prognostic value in 
staging study and the response to radiotherapy (RT) 
treatment with or without chemotherapy.  
Materials and Methods: Radiotherapy planning was 
performed with 18F-FDG PET-CT in 28 patients (p) diagnosed 
of HNSCC between august 2009 and august 2013. 
Male/Female: 23/5. Mean age: 60 years (range: 49-74). 
Location primary tumor: larynx 11 (39%), oropharynx 6 (21%), 
hypopharynx 6 (21%) and oral cavity 5 (18%). Clinical tumor 
stage: III 4 (14%); IVa 23 (82%); IVb: 1 (4%). They were 
treated at our Center with curative intent using RT (mean 
dosis 6943 cGy, range 6600-7000): with or without 
chemotherapy (concurrent n=25 and induction n=14). 
Minimum follow-up 12 months. Response was assessed by 
18F-FDG PET-CT at least 8 weeks after completion of 
radiotherapy (mean 15 weeks, range 8-45). Maximum 
standard uptake value (SUVmax) of primary tumor (T) and 
lymph nodes (N) in staging PET were measured and compared 
in both groups of patients: those with complete response at 
treatment (CR) and those with no complete response (noCR). 
Sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy (Acc) were 
calculated in the response 18F-FDG PET-CT.  
Results: Basal PET mean SUVmax for T and N was 19,48 and 
10.50 respectively. The response 18F-FDG PET-CT showed 
complete metabolic response in 19 p (68%), partial response 
in 5 p (18%) and progression disease in 4 p (14%), with 
evidence of nodal disease in 4 p (14%) (mean SUVmax 4,89) 
and residual tumor in 8 p (29%) (mean SUVmax 8,34). In the 
follow-up period 17 p had no recurrence. Sensitivity, 
specificity, PPV, NPV and Acc of response PET-CT was 88%, 
95%, 88%, 95% and 93% for primary tumor, and 67%, 91%, 50%, 
95% and 88% for nodal disease. Overall survival (OS) and 
disease-free survival (DFS) at 2 years were 79% and 64%, 
respectively. Mean SUVmax of T in CR group and noCR were 
19,33 and 19,68 respectively. Mean SUVmax of N were 9,31 
and 12,41 respectively. We did not find differences 
statistically significant between nodal or primary tumor 
SUVmax and overall survival (p=0,9173 for T, p=0,3165 for N).  
Conclusions: 18F-FDG PET-CT is a useful method for assessing 
response after radical chemoradiotherapy in advanced 
HNSCC, showing a high negative predictive value for primary 
tumor and lymph nodes. In our cohort, higher primary tumor 
and nodal SUVmax was not associated with lower rates of 
survival. Multi-institutional trials are required to establish 
stronger conclusion on this matter. 
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Purpose/Objective: To report initial results of a prospective 
clinical trial aimed to assess instrumental swallowing function 
in nasopharynx and oropharynx cancers after radio or 
chemoradiotherapy using intensity-modulated radiotherapy 
(IMRT). 
Materials and Methods: IMRT was delivered aiming to spare 
the swallowing organ at risk (SWOARs) for Stage II-IV naso and 
oropharynx cancer. Objective instrumental assessment 
included Videofluoroscopy (VFS), Fiberoptic Endoscopic 
Evaluation of Swallowing (FEES) and Oro-Pharyngeal-
Esophageal Scintigraphy (OPES) at baseline and 1,6 and 12 
months after radiotherapy. Dysphagia parameters scores 
were calculated and reported at each exam both after liquid 
(L) and semi-liquid (SL) bolus intake: pre-swallowing 
penetration, aspiration, pharyngeal transit time (PTT) and 
hypopharyngeal retention index (HPRI) 
Results: Overall 20 patients (6 Nasophaynx and 14 
Oropharynx) completed treatment and instrumental 
assessment at 1 month. Correlations between the pre and 
post-treatment changes in HPRI scores resulted statistically 
significant both at FEES-L (p=0,021) and SL (p=0,02) and at 
VFS-L (p=0,008) and SL (p=0,005). Moreover significant 
relationships between baseline and 1 month HPRI score at 
FEES-L and FEES-SL (p=0,005) as well as at VFS-L and VFS-SL 
(p<0,001), were observed. Differently, PTT resulted not 
significantly affected by radiotherapy (p>0,2). Only few 
patients experienced pre-swallowing penetration (1 patient 
with base of tongue cancer at FEES-L and SL) and aspiration 
(1 patient with nasopharynx cancer at OPES-L and FEES-SL) 
after radiotherapy 
Conclusions: Our early results showed that radiotherapy 
significantly increased the post-swallowing HPRI. Longer 
follow-up will be necessary to evaluate if the increase of 
HPRI is related to an high risk to develop late aspiration. 
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Purpose/Objective: It was previously shown that SUVmax of 
pretreatment 18-Fluordesoxyglucose PET/CT (FDG-PET) of 
the primary in locally advanced lung cancer patients was 
associated with higher risk of distant failure (DF) (V.J. Nair et 
al., 2014). The following analysis tries to find similarities in 
case of locally advanced, non-metastatic patients with 
